Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SLAM-C: Long-term PEG-IFN in HIV/HCV Coinfected Subjects
NCT00078403Phase 2Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Jul 2004
- Primary completion
- May 2007
- Modality
- rProtein (Recombinant Protein), Biologic
- Countries
- 2
01
Overview
Phase 2, randomised, open-label trial of peginterferon alfa-2a in hepatitis C (HCV) (3 arms), sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoint: Time-scaled Change in Metavir Liver Fibrosis Score at Week 72. Started Jul 2004; status: completed.
02
Drugs
peginterferon alfa-2a
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT00078403.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00078403.